Please login to the form below

Not currently logged in
Email:
Password:

Dr Georg Buchner joins Silence Therapeutics

He assumes a business development role at the London-based biotech

London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

He was formerly VP of Corporate & Business Development at Novacta Biosystems and prior to that served as business development director at Haptogen. During that time he was instrumental in the sale of the Haptogen business to Wyeth, now part of Pfizer, in 2007

At Silence Georg will work with Tony Sedgwick, who was appointed chief business officer in September, as part of the company's strategy to continue to broaden its collaborations with global pharmaceutical and biotechnology companies.

Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner to Silence. Georg has a strong track record in business development and his experience will strengthen our growing business development team as we seek to expand our increasing list of corporate partnerships.”

10th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics